What do Reddit users say about the tesamorelin ipamorelin blend? We break down reported dosing, side effects, and legal status in plain English.
The tesamorelin ipamorelin blend is a combination of two synthetic peptides that Reddit users discuss mainly for fat loss, growth hormone release, and body composition. Tesamorelin is the active ingredient in Egrifta, an FDA-approved drug for HIV-associated lipodystrophy, while ipamorelin is a research peptide that is not approved for human use in the United States. No clinical trial has tested the two peptides together as a blend, so nearly everything written about the combination comes from personal anecdotes rather than controlled data.
What Tesamorelin and Ipamorelin Actually Are
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It binds GHRH receptors in the pituitary gland and triggers a pulse of growth hormone, which is why it has been studied for visceral fat reduction in people with HIV-related fat redistribution.
Ipamorelin is a selective ghrelin receptor agonist, sometimes called a growth hormone secretagogue. It stimulates GH release through a completely different receptor, which is why forum users assume the two work well together.
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| Peptide class | GHRH analog | Ghrelin receptor agonist |
| Best-studied use | Visceral fat in HIV lipodystrophy | GH release (research only) |
| FDA status | Approved as Egrifta for one condition | Not approved for human use |
| Reported half-life | Roughly 30 minutes | About 2 hours |
| Typical route | Subcutaneous injection | Subcutaneous injection |
Why Reddit Reports About This Blend Are So Mixed
Anyone who types tesamorelin and ipamorelin stack reddit into a search bar will find threads stretching back years, and the reports rarely agree with each other. Some users describe noticeable fat loss around the waist within a few weeks. Others say they felt nothing beyond water retention and a tingling sensation in their hands.
A few reasons explain the gap between experiences:
- Vial labels vary widely, and a 12 mg blend from one vendor may not match the ratio sold by another.
- Most users are also training, dieting, or running other compounds, so it is impossible to isolate what did what.
- Underground peptides are frequently mislabeled, underdosed, or entirely different from what the label claims.
- Individual GH response varies with age, body fat, sleep, and genetics.
Reddit is useful for spotting patterns, but a thread with 40 replies is not evidence. It is a collection of self-reported experiences with no control group, limited bloodwork verification, and almost no follow-up.
Dosing Patterns People Report
A search for tesamorelin cjc1295 ipamorelin 12mg blend dosage reddit usually returns photos of vials rather than clear instructions, because the 12 mg figure refers to total peptide mass, not the dose of any single component. Users then divide the total by the number of injections per vial and estimate from there.
A 2x blend tesamorelin 10mg ipamorelin 5mg vial, for example, contains 15 mg of total peptide in a 10:5 ratio. Common vendor labels look roughly like this:
| Label seen online | Tesamorelin | CJC-1295 (no DAC) | Ipamorelin | Total |
|---|---|---|---|---|
| Tesamorelin / Ipamorelin 2x blend | 10 mg | None | 5 mg | 15 mg |
| Three-peptide 12 mg blend | 5 mg | 2 mg | 5 mg | 12 mg |
| Three-peptide 15 mg blend | 5 mg | 5 mg | 5 mg | 15 mg |
Doses people mention most often in threads:
- Tesamorelin: 1 mg to 2 mg injected once daily, usually before bed. The FDA-labeled Egrifta dose is 1.4 mg or 2 mg daily for its approved indication.
- Ipamorelin: 100 mcg to 300 mcg per injection, one to three times daily.
- CJC-1295 without DAC: about 100 mcg per injection, often paired with ipamorelin.
None of those numbers come from a trial of the blend itself, and combining peptides does not change their individual risk profiles.
Reported Benefits and Side Effects
Discussions about tesamorelin cjc1295 ipamorelin 12mg blend benefits tend to focus on the same handful of outcomes: reduced belly fat, deeper sleep, faster recovery between workouts, and improved skin. Only the visceral fat effect has solid clinical support, and that support applies to tesamorelin alone in a specific patient population, not to a multi-peptide blend.
Side effects that come up repeatedly include:
- Injection site redness, itching, or firm lumps
- Water retention and puffiness in the face, hands, or feet
- Numbness or tingling in the hands and wrists, a common sign of elevated growth hormone
- Increased appetite, especially with ipamorelin
- Headache, joint aches, and fatigue during the first weeks
- Rising IGF-1 and possible changes in blood sugar
Tesamorelin's prescribing information warns about increased IGF-1, fluid retention, and effects on glucose metabolism. Anyone with a history of diabetes, pituitary disease, or hormone-sensitive cancer should treat these peptides as off-limits without a doctor's involvement.
Sourcing, Legal Status, and Quality Risk
Search interest in a tesamorelin ipamorelin blend for sale is high, but the legal picture is not straightforward. Tesamorelin itself is a prescription drug in the United States. Ipamorelin and CJC-1295 are sold as research chemicals labeled for laboratory use only, and the FDA has not approved them for any human use. Buying them for personal injection sits in a gray zone that varies by state and by how the product is marketed.
Quality is the bigger practical problem. Independent testing of gray-market peptides has repeatedly found vials that contain less peptide than the label claims, the wrong peptide entirely, or bacterial contamination. A certificate of analysis from the seller is not the same thing as third-party testing, and many certificates shared in forums are recycled or fabricated.
If someone already uses tesamorelin under a prescription for its approved indication, adding an unapproved peptide on top is a decision to make with a physician who can monitor IGF-1, fasting glucose, and other markers over time.
Bottom Line
Key takeaways from the available information:
- The tesamorelin ipamorelin blend is not FDA-approved, and no human trial has studied the combination.
- Tesamorelin is FDA-approved only as Egrifta for HIV-associated lipodystrophy, at 1.4 mg or 2 mg daily.
- Ipamorelin is not approved for human use in the United States.
- Reddit threads describe benefits that are plausible but unverified, alongside side effects that are real and dose-related.
- Vial quality, not dose, is often the largest variable in user-reported outcomes.
- Anyone considering these peptides should speak with a healthcare professional first.
Frequently Asked Questions
Is the tesamorelin ipamorelin blend FDA-approved?
No. Tesamorelin is FDA-approved only as Egrifta for HIV-associated lipodystrophy, and ipamorelin is not approved for any human use in the United States. A blend of the two is not an approved product, and no clinical trial has tested them together.
What dosage do Reddit users report for a tesamorelin ipamorelin blend?
Most threads mention 1 mg to 2 mg of tesamorelin and 100 mcg to 300 mcg of ipamorelin injected before bed, sometimes with about 100 mcg of CJC-1295 without DAC. Those numbers are borrowed from separate studies of each peptide, not from research on the blend, so they should not be treated as a safe or proven protocol.
What side effects do people report from the blend?
The most common complaints are injection site reactions, water retention, tingling or numbness in the hands, increased appetite, and headaches. Tesamorelin's label also warns about elevated IGF-1 and changes in blood sugar, which is why monitoring by a healthcare professional matters if someone is using it at all.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.